155 related articles for article (PubMed ID: 37470495)
1. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract][Full Text] [Related]
2. MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma.
Li C; Zhang K; Liu A; Yue T; Wei Y; Zheng H; Piao JG; Li F
Int J Pharm; 2021 Nov; 609():121209. PubMed ID: 34678398
[TBL] [Abstract][Full Text] [Related]
3. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
4. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
5. Liposome-Coated Arsenic-Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma.
Jin Z; Yi X; Yang J; Zhou M; Wu P; Yan G
Int J Nanomedicine; 2021; 16():3775-3788. PubMed ID: 34113100
[TBL] [Abstract][Full Text] [Related]
6. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
7. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
10. 'Prodrug-Like' Acetylmannosamine Modified Liposomes Loaded With Arsenic Trioxide for the Treatment of Orthotopic Glioma in Mice.
Wang N; Zhang W; Hu D; Jiang L; Liu X; Tang S; Zhou X; Liu T; Tang X; Chai Y; Li M; Peng H; Du Z
J Pharm Sci; 2020 Sep; 109(9):2861-2873. PubMed ID: 32534027
[TBL] [Abstract][Full Text] [Related]
11. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
12. Angiopep-2-modified calcium arsenite-loaded liposomes for targeted and pH-responsive delivery for anti-glioma therapy.
Xu H; Li C; Wei Y; Zheng H; Zheng H; Wang B; Piao JG; Li F
Biochem Biophys Res Commun; 2021 Apr; 551():14-20. PubMed ID: 33714754
[TBL] [Abstract][Full Text] [Related]
13. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
[TBL] [Abstract][Full Text] [Related]
14. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
15. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
17. A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: An application for bladder cancer treatment.
Vila-Caballer M; Codolo G; Munari F; Malfanti A; Fassan M; Rugge M; Balasso A; de Bernard M; Salmaso S
J Control Release; 2016 Sep; 238():31-42. PubMed ID: 27444816
[TBL] [Abstract][Full Text] [Related]
18. pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
Yang MM; Wilson WR; Wu Z
Int J Pharm; 2017 Jan; 516(1-2):323-333. PubMed ID: 27871834
[TBL] [Abstract][Full Text] [Related]
19. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
20. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
